AAIC 2025 Abstract
Clinical and Pharmacologic Profile of a Subcutaneous Lecanemab Formulation
Trial in peopleInterventions
Abstract
Background: Lecanemab 10 mg/kg every 2 weeks (Q2W) intravenously was shown in the Clarity AD trial to slow the progression of Alzheimer’s disease (AD).
